PHP Biotech to Present Nanobody Panel and Sponsor 3rd Annual Oncology Venture, Innovation & Partnering Summit

September 25, 2026

Southlake, Texas - September 25, 2026 -

PHP Biotech, a US-based biotechnology company specializing in nanobody and translational biotechnology, will participate in the 3rd Annual Oncology Venture, Innovation & Partnering Summit as both a featured presenter and an event sponsor. The Summit takes place October 19?20, 2026, at the Kimpton Marlowe Hotel in Cambridge, Massachusetts, and brings together senior pharma executives, Private Equity investors, oncology clinicians and researchers, along with other industry leaders focused on oncology innovation and partnering. The agenda includes a keynote address with the subject ?Undruggable? Targets to Transformative Medicines: The Journey to Bring a Novel Therapeutic Modality to Patients.

At 4:10 PM on October 19th, PHP Biotech will lead a 20-minute panel titled "Beyond the Undruggable:" What if Nanobodies Redefine the Future of Cancer Therapy? The panel will introduce PHP Biotech?s proprietary platform, with PHP53-nb as a proof of concept and the first product developed using this platform, highlighting its selective effect on tumor cells, enhanced biodistribution and potential to open new theragnostic possibilities in oncology. Robert Gahagen, Chief Executive Officer of PHP Biotech, will moderate the panel and introduce Patrícia Bezerra, the company's scientific leader and head of research and

development. At 5:00 PM at the end of the first day there will be a Welcome Networking Reception sponsored by PHP Biotech for all participants to meet and discuss the various topics presented during the panels throughout the day.

In addition to the panel, PHP Biotech is sponsoring an onsite reception later in the day, giving attendees an informal setting to meet the company's team. On October 20 at 10:15 AM, the company will host a roundtable discussion, a moderated question-and-answer forum where interested parties can speak with PHP Biotech's scientific experts in greater depth than the panel format allows.

"Twenty minutes is enough to introduce the science, but meaningful conversations take more time," Gahagen said. "The reception and the roundtable give investors, clinicians, and potential partners the chance to ask detailed questions and engage directly with the people doing the work."

Joining Gahagen and Bezerra at the Summit will be Moacyr Bighetti, Founder and Chairman; Dr. Eduardo Braun, oncologist and Board Member; Prof. Marcelo Baruffi, PhD, nanobody scientist; and Dr. Fabio Jung, oncologist and Partner at Synchro. Together, the group brings leadership, research, and clinical oncology perspectives to the company's discussions at the event.

The presentation will focus on GEN01-AD, PHP Biotech's proprietary intracellular nanobody platform, which integrates therapeutic functionality directly into humanized nanobodies to reach targets beyond the cell surface. Its first proof of concept, PHP53-nb, is designed to enter tumor cells and restore the function of the p53 protein, a key regulator associated with several aggressive cancers. The company reports three therapeutic assets and four U.S. patent applications to date.

PHP Biotech encourages investors, researchers, clinicians, and prospective partners interested in its technology to attend.

PHP Biotech is a US-based biotechnology company focused on nanobody and translational biotechnology. The company develops novel therapeutic nanobodies intended to target and destroy cancer cells, with a lead candidate, PHP53-nb, designed to reactivate the functionality of the p53 protein. Its team of healthcare entrepreneurs, scientists, and researchers conducts research and development aimed at addressing aggressive cancers, including triple-negative breast cancer. The company maintains a nanobody platform intended to support a variety of therapeutic applications across its development pipeline.

###

For more information about PHP Biotech, contact the company here:PHP BiotechRobert Gahagen(888) 739-6972contact@phpbiotech.com550 Reserve St. STE 190?Southlake, TX 76092

PHP Biotech

Our goal: better treatments for aggressive cancers. We developed PHP53-nb?pairing our 3-NAntC p53-reactivating peptide with the GEN01-AD nanobody platform to restore tumor-suppressing function. Promising results in TNBC and pancreatic cancer.

Website: https://phpbiotech.com/

Email: contact@phpbiotech.com

Phone: (888) 739-6972